Companies ›Healthcare ›TNXP.O

TNXP.O — NASDAQ Diversified Pharmaceuticals

Tonix Pharmaceuticals Holding Corp

$10,54

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

-975,0 %

ROE

-50,6 %

Net margin

-946,2 %

Debt / equity

0,00

Beta

—

52w range

—

Volume

2,9k

Day range

$12,08–$12,67

Prev close

$12,64

Open

$12,63

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of chronic and infectious diseases, with a pipeline including investigational drugs for post-traumatic stress disorder (PTSD) and other indications.

Business. Tonix Pharmaceuticals Holding Corp (TNXP.O) is a healthcare company operating in the pharmaceuticals industry, primarily engaged in pharmaceuticals and medical research. The firm generates revenue through product sales and is listed on the NASDAQ stock exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not provided in the available data.

Classification99 %

SectorHealth Care

Industry groupDiversified Pharmaceuticals

Generated · model-assisted

Sell-side consensus

BUY2 analysts

2 buy0 hold0 sell

Avg 12m price target54,33

Analyst recommendations

2 analysts · consensus Buy

Buy2

Hold0

Sell0

12-month price target

54,33

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

2 analysts · indicative

Ownership→

AQR Capital Management, LLC

largest disclosed fund holder

Profitability→

-50,6 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning TNXP.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to TNXP.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

Briefing · model-assisted

Tonix Pharmaceuticals Holding Corp (TNXP.O) has entered the scope of this analysis, marking the first available data point for the ticker. As a result, there is no prior basis for computing material changes or deltas in financial performance or operational metrics. The current snapshot serves as the foundational baseline for future monitoring of the company’s trajectory. The most notable activity detected involves a series of new institutional holdings added to the company’s shareholder registry. Multiple investors initiated positions as of late 2025 and early 2026, with filings detected on June 20, 2026. These additions represent fresh capital interest in the stock, although the specific identities of the investors are not disclosed in the available data. Among the new holders, one investor (ID 465) established a position of 673,605 shares valued at approximately $10.5 million as of December 31, 2025. Other notable additions include an investor (ID 499) holding 231,678 shares valued at roughly $3.2 million as of March 31, 2026, and another (ID 467) with 230,607 shares valued at approximately $3.2 million for the same period. Smaller positions were also added by several other entities, with share counts ranging from 13,070 to 29,790. Tonix Pharmaceuticals currently reports 17 top holders and has no listed analyst coverage or index memberships. The absence of analyst estimates and the initial nature of this data mean that the significance of these new holdings must be viewed in isolation, without comparative context from prior quarters or market consensus. Future updates will be required to determine if these initial positions signal a broader shift in investor sentiment.

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Tonix Pharmaceuticals Holding Corp (TNXP.O) is a healthcare company operating in the pharmaceuticals industry, primarily engaged in pharmaceuticals and medical research. The firm generates revenue through product sales and is listed on the NASDAQ stock exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not provided in the available data.

Classification99 %

SectorHealth Care

Industry groupDiversified Pharmaceuticals

AI synthesis

GENERATED

Tonix Pharmaceuticals has a strong liquidity position, with $207.6 million in cash and equivalents and no long-term debt, resulting in a debt-to-equity ratio of 0.0 and a current ratio of 7.42. However, the company reported negative operating and free cash flows of -$99.8 million and -$125.5 million, respectively, indicating ongoing operational cash burn.

Profitability metrics are negative, with a return on equity of -50.59% and a return on assets of -44.75%. These figures are significantly below the industry median for pharmaceutical companies, which typically exhibit positive returns due to high-margin product sales and R&D efficiency. Tonix's operating loss of $127.8 million and net loss of $124.0 million further highlight the company's current unprofitability.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regulatory, clinical, and market risks in its primary therapeutic areas, particularly PTSD and related conditions.

Looking ahead, Tonix is expected to maintain a negative growth trajectory, with no disclosed revenue growth in the current fiscal year and no clear path to profitability in the next fiscal year. The company's capital expenditures of -$3.4 million suggest minimal investment in new facilities or equipment, which may limit long-term capacity for product development and commercialization.

Risk factors include liquidity risk due to ongoing negative cash flows and the absence of long-term debt, which could limit flexibility in the event of unexpected expenses or delays in clinical trials. Dilution risk is currently low, with no immediate filing-based flags detected, and shares outstanding remain unchanged between basic and diluted shares.

Recent events include the continued development of its lead candidate, TNX-102 SL, for PTSD, with no recent regulatory approvals or major clinical trial results disclosed. The company has not issued new equity in the latest reporting period, and no significant changes in management or strategic direction have been reported.

Key takeaways

Tonix Pharmaceuticals has strong liquidity but is currently unprofitable with negative cash flows.
The company's return on equity and assets are significantly below industry norms.
Revenue and product concentration pose operational and regulatory risks.
No immediate dilution or liquidity risks are present, but ongoing cash burn remains a concern.
The company lacks geographic and segment diversification, increasing exposure to market-specific risks.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$10,54

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$245.2M

Net cashⓘ

$207.6M

Current ratioⓘ

7.4

Debt / equityⓘ

0.0

ROAⓘ

-44.8%

ROEⓘ

-50.6%

Cash conversionⓘ

81.0%

CapEx / revenueⓘ

-25.7%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs TNXP · multiples and returns

MCK—

Mckesson Corp

$827,14

102,6B USD

P/E

21,2x

— vs self

Div yield

0,4 %

— vs self

ROE

-219,2 %

-168,7 vs self

COR—

Cencora Inc

$308,37

60,2B USD

P/E

36,4x

— vs self

Div yield

0,8 %

— vs self

ROE

45,7 %

+96,3 vs self

CAH—

Cardinal Health Inc

$235,60

57,0B USD

P/E

36,7x

— vs self

Div yield

0,9 %

— vs self

ROE

-55,9 %

-5,3 vs self

DB—

DB.V

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

REGN—

REGENERON PHARMACEUTICALS, INC.

$757,99

81,0B USD

P/E

15,5x

— vs self

Div yield

—

— vs self

ROE

14,2 %

+64,8 vs self

BIIB—

BIOGEN INC.

$201,74

29,6B USD

P/E

21,3x

— vs self

Div yield

—

— vs self

ROE

7,5 %

+58,1 vs self

ZTS—

Zoetis Inc

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

GRFS—

Grifols SA

$7,86

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-9,62

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-25 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-10,70
Revenue	—no estimate	—no estimate	30,9M USD
Operating income	—no estimate	—no estimate	-175,6M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Corporate eventM&A horizon

M&A probabilityconf 5 %

Probability

5 %

Base rate

3 %

Band

—

180-day horizon · target 2027-01-16 · 1,8× base rate

No acquirer candidates identified by the signal model.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution3 analysts

Strong buy0

Buy3

Hold0

Sell0

Strong sell0

12-month price target$46,25 · Median $49,00

Low $22,00High $65,00

Operating income · consensus-175,6M USD

EPS surprise

−36,2 %

reported vs consensus · miss

Revenue surprise

−57,6 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$34,00

Mean$54,33

Median$64,00

High$65,00

Spot$10,54

+415.5 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin-975,0 %Bottom quartile

Net Margin-946,2 %Bottom quartile

ROE-50,6 %Bottom quartile

Capex / Rev-25,7 %Bottom quartile

D/E0,00Above median

Cash Conv0,81Above median

Corporate actions / M&A

M&A probabilityconf —

Probability

5 %

Base rate

3 %

Band

Moderate

180-day horizon · target 2027-01-16 · 1,8× base rate

No acquirer candidates identified by the signal model.

Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 762 699 sh18 grants13 insiders

OLUKOTUN ADEOYE YDirector · Stock Option → Common StockAcquired 22 700 @ $13,28grant · 2026-05-12
Hunter James Randolph JrDirector · Stock Option → Common StockAcquired 22 700 @ $13,28grant · 2026-05-12
Treco JamesDirector · Stock Option → Common StockAcquired 22 700 @ $13,28grant · 2026-05-12
GRANGE DAVID LDirector · Stock Option → Common StockAcquired 22 700 @ $13,28grant · 2026-05-12
BAGGER RICHARD HDirector · Stock Option → Common StockAcquired 22 700 @ $13,28grant · 2026-05-12
Taylor Carolyn E.Director · Stock Option → Common StockAcquired 22 700 @ $13,28grant · 2026-05-12
Stillwell Richard NewcombDirector · Stock Option → Common StockAcquired 22 700 @ $13,28grant · 2026-05-12
Bell Margaret SmithDirector · Stock Option → Common StockAcquired 22 700 @ $13,28grant · 2026-05-12
SAENGER BRADLEYChief Financial Officer · Stock Option → Common StockAcquired 39 012 @ $14,29grant · 2026-02-24
MORRIS JESSICA EDGARChief Operating Officer · Stock Option → Common StockAcquired 39 011 @ $17,86grant · 2026-02-24
MORRIS JESSICA EDGARChief Operating Officer · Stock Option → Common StockAcquired 39 012 @ $14,29grant · 2026-02-24
SULLIVAN GREGORY MChief Medical Officer · Stock Option → Common StockAcquired 39 012 @ $14,29grant · 2026-02-24
SAENGER BRADLEYChief Financial Officer · Stock Option → Common StockAcquired 39 011 @ $17,86grant · 2026-02-24
LEDERMAN SETHDirector, Chief Executive Officer · Stock Option → Common StockAcquired 134 504 @ $14,29grant · 2026-02-24
SULLIVAN GREGORY MChief Medical Officer · Stock Option → Common StockAcquired 39 011 @ $17,86grant · 2026-02-24
Fogarty SiobhanChief Technology Officer · Stock Option → Common StockAcquired 39 012 @ $14,29grant · 2026-02-24
Fogarty SiobhanChief Technology Officer · Stock Option → Common StockAcquired 39 011 @ $17,86grant · 2026-02-24
LEDERMAN SETHDirector, Chief Executive Officer · Stock Option → Common StockAcquired 134 503 @ $17,86grant · 2026-02-24

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

Tonix Pharmaceuticals Holding Corp Market data — financials · 2026-05-29
Tonix Pharmaceuticals Holding Corp Market data — analyst estimates · 2026-05-29
Tonix Pharmaceuticals Holding Corp Market data — ESG · 2026-05-29

Ownership & reference

Top holders

AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$2M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$3M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$4M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$1M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$11M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$3M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$1M
American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$0M
AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$0M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Invesco QQQ TrustFunds · as of 2026-03-310,00 %$0M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M

Insider activity

Net buying7 buys · 0 sellsnet $443K5 insiders · last 365d

SAENGER BRADLEYChief Financial Officer · Common Stock, $0.001 par valueOther 1 453 @ $10,91$16K · 2026-06-30
Taylor Carolyn E.Director · Common Stock, $0.001 par valueBought 1 415 @ $10,55$15K · 2026-06-12
LEDERMAN SETHDirector, Chief Executive Officer · Common Stock, $0.001 par valueBought 5 000 @ $11,79$59K · 2026-06-09
Stillwell Richard NewcombDirector · Common Stock, $0.001 par valueBought 5 000 @ $11,65$58K · 2026-06-08
LEDERMAN SETHDirector, Chief Executive Officer · Common Stock, $0.001 par valueBought 5 000 @ $12,62$63K · 2026-03-31
LEDERMAN SETHDirector, Chief Executive Officer · Common Stock, $0.001 par valueBought 15 000 @ $14,89$223K · 2026-03-18
SAENGER BRADLEYChief Financial Officer, 10% owner · Common Stock, par value $0.001Other 701 @ $13,42$9K · 2025-12-31
Taylor Carolyn E.Director · Common Stock, par value $0.001Bought 418 @ $36,03$15K · 2025-08-21
Treco JamesDirector · Common Stock, par value $0.001Bought 250 @ $36,00$9K · 2025-08-20

Short positioning

3.6Mshares short+0.1% vs prior

7.23days to cover

48.7%short of daily vol

255fails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

TNXP.OCanonical

NASDAQ · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00M&A prob5 %Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

Return on assets (FY 2025-12-31): -44.7%Derived (calculated)
Net margin (FY 2025-12-31): -946.2%Derived (calculated)
Return on equity (FY 2025-12-31): -50.6%Derived (calculated)
Current ratio (FY 2025-12-31): 7.42xDerived (calculated)
Debt-to-equity (FY 2025-12-31): 0.13xDerived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): 2,707.5%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 110.2%Derived (calculated)
Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -14.5%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 91.7%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 91.7%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): 4.6%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -63.9%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): 8.0%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): 11.3%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): 29.8%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 75.7%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): 70.2%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 37.2%Derived (calculated)
Net income (annual): USD -124.02MSEC XBRL filing
Revenue (annual): USD 13.11MSEC XBRL filing
Operating income (annual): USD -125.7MSEC XBRL filing
Total assets (annual): USD 277.17MSEC XBRL filing
Current liabilities (annual): USD 30.84MSEC XBRL filing
Total liabilities (annual): USD 32.02MSEC XBRL filing

Showing 24 of 56 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: insider_flow_signal (90d)

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)

2026-06-30INSIDERSAENGER BRADLEY transacted 1.5k sh Common Stock, $0.001 par value — Chief Financial Officer ~$16k

2026-06-21 02:57 UTCHOLDERInstitutional holding changed

2026-06-21 02:57 UTCHOLDER15 institutional position changes flagged

2026-06-12 00:00 UTCINSIDER3 insider transactions — 2026-06 · net buy $132k

2026-06-12INSIDERTaylor Carolyn E. bought 1.4k sh Common Stock, $0.001 par value — Director ~$15k

2026-06-09INSIDERLEDERMAN SETH bought 5.0k sh Common Stock, $0.001 par value — Director, Chief Executive Officer ~$59k

2026-06-08FILING8-K filing →

2026-06-08INSIDERStillwell Richard Newcomb bought 5.0k sh Common Stock, $0.001 par value — Director ~$58k

2026-05-27FILING8-K filing →

2026-05-15FILINGCURRENT REPORT →

2026-05-12 00:00 UTCINSIDER8 insider transactions — 2026-05 8 derivative

2026-05-12INSIDERStillwell Richard Newcomb acquired 22.7k sh Stock Option — Director

2026-05-12INSIDEROLUKOTUN ADEOYE Y acquired 22.7k sh Stock Option — Director

2026-05-12INSIDERBell Margaret Smith acquired 22.7k sh Stock Option — Director

2026-05-12INSIDERGRANGE DAVID L acquired 22.7k sh Stock Option — Director

2026-05-12INSIDERTreco James acquired 22.7k sh Stock Option — Director

2026-05-12INSIDERBAGGER RICHARD H acquired 22.7k sh Stock Option — Director

2026-05-12INSIDERTaylor Carolyn E. acquired 22.7k sh Stock Option — Director

2026-05-12INSIDERHunter James Randolph Jr acquired 22.7k sh Stock Option — Director

2026-05-11FILINGCURRENT REPORT →

2026-05-11FILINGQUARTERLY REPORT →

2026-05-07FILINGCURRENT REPORT →

2026-05-06FILINGCURRENT REPORT →

2026-05-01FILINGCURRENT REPORT →

2026-04-29FILINGCURRENT REPORT →

2026-04-23FILINGCURRENT REPORT →

2026-03-31 00:00 UTCINSIDER2 insider transactions — 2026-03 · net buy $286k

Showing the 40 most recent of 60 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread